Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants

NCT01494740 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

312

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: split-virion, non-adjuvanted vaccine of 7.5 μg
BIOLOGICAL: split-virion, non-adjuvanted H1N1 vaccine of 15 μg
BIOLOGICAL: split-virion, non-adjuvanted vaccine of seasonal influenza

Sponsor

Shanghai Institute Of Biological Products